Andere Kunden interessierten sich auch für
![Avian Influenza and Newcastle Disease]( "Avian Influenza and Newcastle Disease")
Avian Influenza and Newcastle Disease74,99 €![Immunology of HIV Infection]( "Immunology of HIV Infection")
Immunology of HIV Infection246,99 €![Retroviral Immunology]( "Retroviral Immunology")
Retroviral Immunology89,99 €![Retroviral Immunology]( "Retroviral Immunology")
Retroviral Immunology122,99 €![Sars- And Other Coronaviruses]( "Sars- And Other Coronaviruses")
Sars- And Other Coronaviruses81,99 €![New Antibiotic Targets]( "New Antibiotic Targets")
New Antibiotic Targets91,99 €![Bacterial Infections of Humans]( "Bacterial Infections of Humans")
Bacterial Infections of Humans373,99 €
This book brings together experts in the field of human retroviral pathogenesis, vaccine development, and the clinical treatment of AIDS. The problems facing the development of an effective vaccine against HIV-1 is the ability of the virus, particularly in the immunogenic envelope glycoprotein, to undergo amino acid hypervariability, thus making a vaccine against one envelope glycoprotein ineffective against other viruses due to their mutability.
The discovery of the human T cell leukemia virus type I in the late 1970s heralded a new era in retrovirology. For the first time, it was demonstrated that a retrovirus could play a role in the development of a human disease, in this case adult T cell leukemia (ATL). Several years later, the acquired immunodeficiency syndrome (AIDS) epidemic began, and it was dem- strated that a retrovirus, originally designated the human T cell lymp- tropic virus type 3, was the causal agent of this syndrome. This virus, later named the human immunodeficiency virus type 1 (HIV-1), has since been extensively studied in terms of its pathogenesis as well as its ability to elicit immune responses. In that time, a tremendous amount of information has been obtained about the virus. Although recent drug regimens have been useful in significantly lowering viral loads and perhaps maintaining an asymptomatic state among individuals infected with HIV-1, an established "cure" for AIDS eludes us. In addition, the effective drug therapies are very expensive, and are not available to infected people in the third world, where greater than 90% of new infections occur. Furthermore, the development of viral resistance against the drug therapies is an additional concern. Despite extensive study, no effective vaccine has been developed. One of the problems in developing an effective vaccine against HIV-1 is the ability of the virus, particularly in the immunogenic envelop glycoprotein, to undergo amino acid hypervariability.
Hinweis: Dieser Artikel kann nur an eine deutsche Lieferadresse ausgeliefert werden.
The discovery of the human T cell leukemia virus type I in the late 1970s heralded a new era in retrovirology. For the first time, it was demonstrated that a retrovirus could play a role in the development of a human disease, in this case adult T cell leukemia (ATL). Several years later, the acquired immunodeficiency syndrome (AIDS) epidemic began, and it was dem- strated that a retrovirus, originally designated the human T cell lymp- tropic virus type 3, was the causal agent of this syndrome. This virus, later named the human immunodeficiency virus type 1 (HIV-1), has since been extensively studied in terms of its pathogenesis as well as its ability to elicit immune responses. In that time, a tremendous amount of information has been obtained about the virus. Although recent drug regimens have been useful in significantly lowering viral loads and perhaps maintaining an asymptomatic state among individuals infected with HIV-1, an established "cure" for AIDS eludes us. In addition, the effective drug therapies are very expensive, and are not available to infected people in the third world, where greater than 90% of new infections occur. Furthermore, the development of viral resistance against the drug therapies is an additional concern. Despite extensive study, no effective vaccine has been developed. One of the problems in developing an effective vaccine against HIV-1 is the ability of the virus, particularly in the immunogenic envelop glycoprotein, to undergo amino acid hypervariability.
Hinweis: Dieser Artikel kann nur an eine deutsche Lieferadresse ausgeliefert werden.